Skip to main content

Table 3 Patients characteristics according to HBV reactivation

From: Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome

Variable HBsAg (−) Diffuse large B-cell lymphoma P value
HBV reactivation Non-HBV reactivation
Sample size 17 149  
Age, years    0.869
  ≤ 60 11 (64.7%) 94 (63.1%)  
  > 60 6 (35.3%) 55 (36.9%)  
Gender    0.911
 Male 9 (52.9%) 81 (54.3%)  
 Female 8 (47.1%) 68 (45.7%)  
B symptom    0.542
 Positive 5 (29.4%) 55 (36.9%)  
 Negative 12 (70.6%) 94 (63.1%)  
IPI score    0.108
 1–2 9 (52.9%) 107 (71.8%)  
 3–5 8 (47.1%) 42 (28.2%)  
LDH    0.264
 Normal 8 (47.1%) 91 (61.1%)  
 Elevated 9 (52.9%) 58 (38.9%)  
Extranodal sites    0.128
  < 2 11 (64.7%) 97 (65.1%)  
  ≥ 2 6 (35.3%) 52 (34.9%)  
Ann Arbor stage    0.135
 I-II 4 (23.5%) 63 (42.3%)  
 III-IV 13 (76.5%) 86 (57.7%)  
HBcAb status    <  0.001
 Positive 17 (100%) 46 (30.9%)  
 Negative 0 (0.0%) 103 (69.1%)  
HBsAb status    0.021
 Positive 8 (47.1%) 110 (73.8%)  
 Negative 9 (52.9%) 39 (26.2%)  
  1. Abbreviations: HBsAb hepatitis B surface antibody, IPI international prognosis index, LDH lactate dehydrogenase